US 12,433,943 B2
Nanoparticle-based influenza virus vaccines and uses thereof
Masaru Kanekiyo, Bethesda, MD (US); Barney S. Graham, Rockville, MD (US); Seyhan Boyoglu-Barnum, Rockville, MD (US); Rebecca A. Gillespie, Bethesda, MD (US); Neil P. King, Seattle, WA (US); Daniel Ellis, Seattle, WA (US); Jing Yang Wang, Seattle, WA (US); George Ueda, Seattle, WA (US); and Jorge Fallas, Seattle, WA (US)
Assigned to UNIVERSITY OF WASHINGTON, Seattle, WA (US); and THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Bethesda, MD (US)
Appl. No. 17/423,565
Filed by The USA, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US); and Unversity of Washington, Seattle, WA (US)
PCT Filed Feb. 7, 2020, PCT No. PCT/US2020/017216
§ 371(c)(1), (2) Date Jul. 16, 2021,
PCT Pub. No. WO2020/163719, PCT Pub. Date Aug. 13, 2020.
Claims priority of provisional application 62/803,218, filed on Feb. 8, 2019.
Prior Publication US 2022/0072120 A1, Mar. 10, 2022
Int. Cl. A61K 39/12 (2006.01); A61K 39/145 (2006.01); A61P 31/16 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/145 (2013.01) [A61P 31/16 (2018.01); C12N 7/00 (2013.01); A61K 2039/55555 (2013.01)] 30 Claims
 
1. A nanoparticle, comprising:
(a) a plurality of first assemblies, each first assembly comprising a plurality of identical first proteins; and,
(b) a plurality of second assemblies, each second assembly comprising a plurality of second proteins;
wherein at least one second assembly comprises at least one second protein joined to an immunogenic portion of an influenza hemagglutinin (HA) protein, thereby forming a fusion protein;
wherein the sequence of the first protein differs from the sequence of the second protein;
wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form the nanoparticle; and,
wherein the nanoparticle displays the immunogenic portion of an HA protein on its surface.